Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Preliminary Evidence for Safe Administration of Ruxolitinib During and After Hematopoietic Stem-Cell Transplantation in Patients with Myelofibrosis
ASH 2021 - Myelofibrosis
Conference Correspondent
— December 13, 2021
Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data.
Read Article
Pelabresib Provides Clinical Benefit in Patients with Myelofibrosis Ineligible or Intolerant to Ruxolitinib Therapy
ASH 2021 - Myelofibrosis
Conference Correspondent
— December 13, 2021
Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset.
Read Article
Sotatercept Improves Anemia in Patients with Myelofibrosis
ASH 2021 - Myelofibrosis
Conference Correspondent
— December 13, 2021
Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept.
Read Article
Early Data Demonstrate Selinexor as Safe and Effective Monotherapy in Patients with Myelofibrosis
ASH 2021 - Myelofibrosis
Conference Correspondent
— December 13, 2021
Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells.
Read Article
Fedratinib Demonstrates Efficacy in Patients with Myelofibrosis with Prior Ruxolitinib Therapy
ASH 2021 - Myelofibrosis
Conference Correspondent
— December 13, 2021
Ruxolitinib is an approved therapy for myelofibrosis but some patients experience serious side effects. Fedratinib is an effective therapeutic option for these patients without development of severe adverse events.
Read Article
Prior Authorization and the Impact on Cancer Care
AVBCC 2020 Summit
Conference Correspondent
— December 21, 2020
Utilization management tools and prior authorization are associated with delays in care for patients and high costs for physicians. In this session, panelists discuss the impact on cancer care, with an eye toward providing appropriate care while minimizing administrative burden.
Read Article
Early-Stage Cancer Diagnosis and Trends
AVBCC 2020 Summit
Conference Correspondent
— December 18, 2020
With more than 1.8 million diagnoses of cancer per year in the United States, identifying malignancies at the earliest stage is priority among physicians. In this session, experts discuss the future of early-stage cancer diagnosis and how to improve cancer screenings.
Read Article
Oncology Nursing and Navigation
AVBCC 2020 Summit
Conference Correspondent
— December 17, 2020
Oncology nurse and patient navigators are playing an ever-increasing role in supporting patients with cancer and their caregivers. In this session, experts discuss the standardized measures and processes used by oncology nurse and patient navigators.
Read Article
COVID-19 Lessons Learned
AVBCC 2020 Summit
Conference Correspondent
— December 16, 2020
In this session, experts discuss the challenges faced at the beginning of the COVID-19 pandemic, how they worked to overcome them, and what lessons they will take with them into the future.
Read Article
Oncology Pharmacy Practice
AVBCC 2020 Summit
Conference Correspondent
— December 15, 2020
Specialized oncology pharmacy programs are playing an ever-increasing role in the complex delivery of care. In this session, panelists discuss the obstacles and successes of specialized oncology pharmacy programs.
Read Article
Page 3 of 44
1
2
3
4
5
6
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma